What Armas Pharmaceuticals does

Armas Pharmaceuticals is a privately held, specialty pharmaceutical company founded in 2018 by John Niemi and headquartered in Freehold, New Jersey. The company commercializes a portfolio of generic injectable, oral solid, and ophthalmic pharmaceutical products in the U.S. market through strategic supply partnerships with manufacturers including Steriscience (exclusive, 2022) and Micro Labs USA (2019). Its product portfolio spans therapeutic categories including antibiotics, anesthetics, oncology, cardiovascular, and ophthalmics, with 30+ products as of recent reporting.

The company operates as a virtual manufacturer model: it does not own production facilities and instead relies on third-party manufacturing partners to supply product, while Armas handles regulatory, commercial, and distribution functions. Products are distributed through major pharmaceutical wholesalers (AmerisourceBergen, Cardinal Health, McKesson, M&D), with contracting support extended to group purchasing organizations (GPOs) and integrated delivery networks (IDNs/IHDs). Customer end-markets are hospitals, healthcare systems, and institutional providers requiring consistent supply of essential generic medications, with a stated emphasis on addressing drug shortages and supply-chain gaps.

Armas is family-controlled (Niemi family), bootstrapped with no disclosed institutional funding, and remains very small in headcount despite a leadership team that collectively carries 100+ years of generic pharmaceutical experience. The business model is a one-time product sales model with pricing not publicly disclosed. The company's stated differentiators are its industry relationships, global manufacturing partnerships, and a focus on supply-chain reliability for essential medications.

Name

Armas Pharmaceuticals

Legal name

Armas Pharmaceuticals, Inc.

Website

https://armaspharmaceuticals.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Armas Pharmaceuticals is a private, New Jersey-based specialty pharmaceutical company that commercializes generic injectable, oral solid, and ophthalmic products in the U.S. market through exclusive supply partnerships and major wholesaler distribution channels serving hospitals and institutional healthcare providers.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

Keywords

• Generic injectables
• Ophthalmic solutions
• Oral solid generics
• Specialty pharmaceuticals
• Pharmaceutical distribution

Headquarters

HQ city

Manalapan

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

1. Generic Pharmaceutical Product Sales: Armas Pharmaceuticals generates revenue through the sale of generic pharmaceutical products including injectables, oral solids, and ophthalmic products. Products are distributed through a network of wholesale distributors and directly to healthcare institutions.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Armas Pharmaceuticals is a specialty pharmaceutical company that commercializes generic injectable, oral solid, and ophthalmic products in the U.S. market through strategic distribution partnerships with global manufacturers (Steriscience, Micro Labs). The company acquires, licenses, and markets a portfolio of more than 30 generic pharmaceutical products spanning antibiotics, anesthetics, cardiovascular drugs, antihistamines, neurological medications, ophthalmics, and oncology treatments, distributed through major wholesalers, GPOs, and direct sales to healthcare institutions.

Product overview

Armas Pharmaceuticals is a specialty pharmaceutical company that offers a diverse portfolio of generic pharmaceutical products, primarily generic injectables and ophthalmic solutions. The product portfolio includes multiple therapeutic categories: antibiotics (Ampicillin, Azithromycin, Ciprofloxacin, Meropenem, Ofloxacin), anesthetics (Lidocaine Jelly, Etomidate), cardiovascular medications (Verapamil, Milrinone, Phenylephrine, Sodium Nitroprusside, Isoproterenol), antihistamines (Diphenhydramine, Ketotifen), neurological medications (Levetiracetam, Caffeine Citrate), ophthalmic products (Erythromycin, Loteprednol, Ofloxacin), and oncology treatments (Azacitidine). The company operates through strategic partnerships for distribution, focusing on hospital and institutional markets. Products are distributed through major wholesalers and group purchasing organizations across the United States.

Differentiator

Problem solved

Functional benefit

Products and services

• Lidocaine Hydrochloride Jelly 2% Topical anesthetic jelly (2% strength, 30mL tube) used in medical applications including urological and endoscopic procedures to provide localized pain relief.
• Ampicillin Injection Penicillin-type antibiotic injection available in multiple dosage strengths including 2g and 10g formulations, used for treating bacterial infections. Reference brand: Principen.
• Ampicillin Sulbactam Injection Combination antibiotic injection (1.5g, 3g, 15g) combining ampicillin with sulbactam beta-lactamase inhibitor for treating bacterial infections. Reference brand: Unasyn.
• Azacitidine Injection Nucleoside analog injection (100mg) used for treatment of myelodysplastic syndromes and acute myeloid leukemia. Reference brand: Vidaza.
• Caffeine Citrate Injection CNS stimulant injection (60mg/3mL) available in cartons of 10 vials. Reference brand: Cafcit.
• Caffeine Citrate Oral Solution Oral solution formulation of caffeine citrate (60mg/3mL) for neonatal apnea treatment. Reference brand: Cafcit.
• Ciprofloxacin and Dexamethasone Otic Suspension Combination otic suspension (0.3%-0.1%/7.5mL) for treating ear infections with anti-inflammatory properties. Reference brand: Ciprodex.
• Cisatracurium Besylate Injection Neuromuscular blocking agent injection (200mg/20mL) in cartons of 10 vials. Reference brand: Nimbex.
• Dexamethasone Phosphate Injection Corticosteroid injection (10mg/mL) for anti-inflammatory and immunosuppressive applications.
• Diphenhydramine Injection Antihistamine injection (50mg/mL) available in multiple pack sizes for allergic reactions. Reference brand: Benadryl.
• Erythromycin Ophthalmic Ointment Antibiotic ophthalmic ointment (0.5%) available in 1g and 3.5g tubes for ophthalmic applications. Reference brand: Ilotycin.
• Erlotinib Tablets (generic Tarceva) Oral solid oncology generic (25mg, 100mg, 150mg strengths) used in oncology treatment. Third oral solid added to the Armas oncology portfolio, generating approximately $150 million annually as of 2019. Reference brand: Tarceva.
• Etomidate Injection General anesthetic injection available in 20mg/10mL and 40mg/20mL strengths. Reference brand: Amidate.
• Isoproterenol Injection Beta-adrenergic agonist injection (1mg/5mL) in cartons of 10 ampuls. Reference brand: Isuprel.
• Ketotifen Fumarate Ophthalmic Solution Antihistamine ophthalmic solution (0.025%/5mL) for treating allergic eye conditions. Reference brand: Zaditor.
• Levetiracetam Injection Antiepileptic injection (500mg/5mL) available in multiple pack configurations. Reference brand: Keppra.
• Lincomycin Injection USP Lincosamide antibiotic injection available in 600mg/2mL and 3000mg/10mL strengths. Reference brand: Lincocin.
• Loteprednol Etabonate Ophthalmic Gel Corticosteroid ophthalmic gel (0.5%/5g) for treating eye inflammation. Reference brand: Lotemax SM.
• Loteprednol Etabonate Ophthalmic Suspension Corticosteroid ophthalmic suspension available in 0.2%/5mL and 0.5%/5mL strengths. Reference brands: Alrex, Lotemax.
• Meropenem Injection Carbapenem antibiotic injection (1g) for treating serious bacterial infections. Reference brand: Merrem.
• Milrinone Lactate Injection Inotropic agent injection (50mg/50mL) for treating heart failure. Reference brand: Primacor.
• Mycophenolate Mofetil Injection Immunosuppressant injection (500mg) in cartons of 4 vials. Reference brand: Cellcept.
• Nafcillin Injection Penicillinase-resistant penicillin antibiotic injection (250mg/2g). Reference brands: Nallpen, Unipen.
• Ofloxacin Ophthalmic Solution Fluoroquinolone antibiotic ophthalmic solution (0.3%/5mL and 0.3%/10mL) for treating eye infections. Reference brand: Ocuflox.
• Oxacillin Injection Penicillinase-resistant penicillin antibiotic injection (2g). Reference brand: Bactocil.
• Phenylephrine HCl Injection Alpha-adrenergic agonist injection available in 10mg/1mL, 50mg/5mL, and 100mg/10mL strengths. Reference brand: Vazculep.
• Piperacillin and Tazobactam Injection Combination antibiotic injection (3.375g and 4.5g) combining piperacillin with tazobactam beta-lactamase inhibitor. Reference brand: Zosyn.
• Sodium Nitroprusside Injection Vasodilator injection (50mg/2mL) for treating hypertensive emergencies. Reference brand: Nitropress.
• Thiamine Injection Vitamin B1 injection (200mg/2mL) for treating thiamine deficiency. Reference brand: Thiamine Hydrochloride.
• Tranexamic Acid Injection Antifibrinolytic injection (1000mg/10mL) in cartons of 10 vials. Reference brand: Cyklokapron.
• Verapamil Injection Calcium channel blocker injection (5mg/2mL) available in cartons of 5 and 25 vials. Reference brand: Calan.

Quantifiable outcome

• Reintroduction of Lidocaine Jelly 2% after more than two years unavailability
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Partnerships

Two partnerships are on record, tiered core.

• SterisciencecoreStrategic or Co-development Partner · 17 March 2022Armas Pharmaceuticals and Steriscience entered an exclusive partnership for the distribution and supply of products for the U.S. market. In the first full year of collaboration, Steriscience intended to launch up to eight products through Armas Pharmaceuticals with first launches commencing in Q2 2022. The market size of these initial launches generates approximately $431M according to IQVIA data. The partnership aims to address supply chain constraints in life-saving antibiotics, anesthetics, and other critical injectable medicines.
• Micro Labs USA, Inc.coreStrategic or Co-development Partner · 28 May 2019Armas Pharmaceuticals and Micro Labs USA announced a strategic collaboration to bring select multisource injectable products to the U.S. market. The first product was Diphenhydramine Injection 50mg/1mL, which had been on the FDA Drug Shortage list since September 2018. Additional product launches were planned for Q2 2019. The market size of these products totaled $100 million annually according to IMS data. Micro Labs is a leading pharmaceutical company in India with presence across R&D, manufacturing, and marketing.

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

Direct peers

• Sagent Pharmaceuticals: Specialty generic injectable manufacturer with deep U.S. hospital channel presence. Directly comparable to Armas — founder John Niemi spent years at Sagent as Senior Director of Business Development. Same customer base (hospitals, GPOs, wholesalers), similar product mix (injectables), and overlapping therapeutic categories.
• Somerset Therapeutics: U.S. specialty generic pharmaceutical company focused on injectables and ophthalmics with a similar virtual/distribution-led commercial model. CEO Joe Niemi previously helped launch Somerset into the U.S. market, providing direct model and product category overlap with Armas.

Broad incumbents

• Hikma Pharmaceuticals: Leading specialty generic injectable manufacturer with strong U.S. institutional franchise across antibiotics, cardiovascular, and oncology. Competes with Armas for the same hospital contracts and GPO formularies, with overlapping therapeutic categories and product types.
• Aurobindo Pharma: One of the largest global generic manufacturers with a substantial U.S. injectable footprint (via Eugia and other subsidiaries). Competes with Armas across antibiotic, anesthetic, and cardiovascular injectables in U.S. hospitals, with far greater scale and product breadth.
• Glenmark Pharmaceuticals: India-based global generics company with a U.S. specialty/generic injectable and oral portfolio. Comparable customer base (wholesalers, GPOs, hospitals), therapeutic categories, and competitive overlap with Armas; CCO Scott Koenig previously held senior roles at Glenmark.
• Dr. Reddy's Laboratories: Global generics manufacturer with significant U.S. specialty injectable portfolio including oncology and hospital products. Direct overlap with Armas' therapeutic mix (Erlotinib-area oncology, antibiotics, cardiovascular) and the same institutional/wholesaler distribution model.
• Eugia Pharma (Aurobindo): Specialty injectables subsidiary of Aurobindo Pharma with a broad U.S. hospital portfolio across oncology, antibiotics, and cardiovascular. Comparable product categories and channel (institutional/wholesaler) as Armas, but with vastly greater scale and parent-company backing.
• Amneal Pharmaceuticals: Diversified U.S. generics and specialty pharma company with injectable division launched by John Niemi at Amneal Biosciences. Therapeutic overlap (injectables, specialty), institutional channel, and prior leadership lineage make Amneal a directly comparable generic injectable incumbent.

Emerging players

• Slayback Pharma: U.S. specialty generics company focused on complex injectables, ophthalmics, and limited-competition products — a near-identical model and therapeutic focus to Armas. Comparable asset-light commercial approach with smaller scale than the major Indian-led generic players.

Others

• Micro Labs: India-headquartered global generics manufacturer and active Armas partner (2019 collaboration for Diphenhydramine and additional injectables totaling ~$100M market). Ecosystem counterpart rather than competitor, but operates in the same U.S. generic injectable supply chain context.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/armas-pharmaceuticals

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Armas Pharmaceuticals